Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11628150 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(6 years from now) | |
US11020361 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(6 years from now) | |
US8334281 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
May, 2030
(6 years from now) |
Gimoti is owned by Evoke Pharma Inc.
Gimoti contains Metoclopramide Hydrochloride.
Gimoti has a total of 3 drug patents out of which 0 drug patents have expired.
Gimoti was authorised for market use on 19 June, 2020.
Gimoti is available in spray, metered;nasal dosage forms.
Gimoti can be used as nasal administration of metoclopramide for treatment of diabetic gastroparesis.
The generics of Gimoti are possible to be released after 16 May, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Jun 19, 2023 |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED;NASAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic